About Next Biomics
NextBiomics was born as a spin-off of the University of Naples FEDERICO II. The strength of NextBiomics is to convey expertise in the field of gastroenterology, pharmacology, genetics and molecular biology and a strong orientation towards the market and its needs.
Our mission is to develop intelligent and green drugs platform based not only on pharmacology but also on the use of data on the patient, his genetics and his microbiome. This is our idea of the medicine of the future with a strong centricity on the holistic vision of the patient.
- “Galactosylated prodrugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug” Patent WO 2010/013279
- “Biological composition based on engineered lactobacillus paracasei subsp. paracasei F19 for the biosynthesis of cannabinoids” – Patent EP 3067058
- “Dietary methods using lactobacillus paracasei subsp. paracasei F19 as NAPE-PLD gene carrier for producing on demand Pea or Oea and relative biological dietary compositions thereof” . Patent EP 3040070
- Engineered E Coli Nissle 1927 expressing SARS CoV2 glicoprotein as a new immunization system against COVID19 infection.
Our Managing Team
Discover more about our management team
More about our Advisors